Elixir Medical today announced four-year results from a study comparing its DynamX coronary bioadaptor system to a leading drug-eluting stent (DES). The BIOADAPTOR randomized controlled trial compared DynamX to the Medtronic Resolute Onyx DES, the current standard of care. It compared the therapies across Japan, Europe and New Zealand. Investigators shared findings from 445 patients […]
Clinical Trials
Insulet initiates study of fully closed-loop insulin delivery in type 2 diabetes
Insulet (Nasdaq:PODD) announced today that it enrolled the first participant in a study of its fully closed-loop automated insulin delivery system for type 2 diabetes. Acton, Massachusetts-based Insulet aims to bring a fully closed-loop (FCL) system to the type 2 diabetes population to further improve glycemic outcomes with less burden for users across diverse settings. […]
More data backs Glucotrack long-term implantable CBGM
Glucotrack (Nasdaq:GCTK) today announced another publication of data supporting its long-term implantable glucose sensor. The latest data, published in The Journal of Diabetes Research, follows a publication last week supporting the system’s feasibility. This study evaluated the long-term accuracy and stability of the fully implantable blood glucose monitoring (CBGM) system in an in-vivo ovine model. […]
Glooko data backs insulin dosing platform
Glooko announced new data reflecting positive outcomes using its EndoTool platform for insulin dosing. EndoTool, a leading software platform, offers capabilities for inpatient insulin dosing and glycemic management. The FDA-cleared platform delivers assistance in optimizing insulin dosing, using a patient-specific algorithm in real-time. It helps reduce the risk of hypoglycemia and helps hospitals meet CMS […]
Abbott has positive drug-eluting scaffold data
Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit features materials similar to dissolving sutures. Unlike metal stents, it’s not a permanent implant, providing support for blocked vessels only for a few months after the blockage is cleared. At that point, the vessel can remain open on its […]
Gluckotrack study supports feasibility of long-term CGM implant
Glucotrack (Nasdaq:GCTK) today announced the publication of a peer-reviewed scientific article evaluating its long-term glucose sensor. The article, published in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal, demonstrated the long-term in-vitro stability of the electrochemical glucose sensors used in the company’s fully implantable continuous blood glucose monitoring (CBGM) system. The company said […]
Medtronic has strong 1-year results for drug-coated balloon
Medtronic (NYSE:MDT) today announced new real-world data from a post-approval study of its In.Pact AV drug-coated balloon (DCB). The IN.PACT AV Access post-approval study demonstrated strong safety and effectiveness for the DCB in the treatment of arteriovenous fistula (AVF) stenoses in patients with end-stage kidney disease on dialysis. The study sought to expand real-world experience through […]
PharmaSens reports positive findings for all-in-one insulin patch pump with CGM
PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. It features the sensor within the Niia device’s insulin infusion cannula. Existing patch […]
Vivani advances development of semaglutide implant
Vivani Medical (Nasdaq:VANI) provided updates this week on its progress and plans related to NPM-139, the company’s semaglutide implant. Alameda, California-based Vivani completed LIBERATE-1, which evaluated its miniature GLP-1 implant in obese and overweight subjects. The company initiated its LIBERATE-1 trial at two centers in Australia at the end of 2024. This study followed FDA […]
Tandem Diabetes Care reports positive findings for Control-IQ in low-bolusing youths
Tandem Diabetes Care (Nasdaq:TNDM) has shared new findings supporting the use of its Control-IQ technology in type 1 diabetes. San Diego-based Tandem’s study aimed to assess the differences in time in range (TIR) between automated insulin delivery (AID) systems in youth with low bolus frequency. It compared Tandem Control-IQ technology with an undisclosed disposable patch-based […]
